Table 3 Parameters associated with time to disease progression by uni- and multivariate analysis (Cox proportional hazards model)
From: Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
N | Univariate HR | 95% CI | P -value | Multivariate HR | 95% CI | P -value | |
|---|---|---|---|---|---|---|---|
WHO PS | |||||||
0–1 | 22 | 1 | |||||
2–3 | 6 | 1.77 | 0.62–4.35 | 0.26 | |||
Time from metastatic diagnosis | |||||||
⩽15 Months | 9 | 1 | |||||
>15 Months | 19 | 0.47 | 0.18–1.17 | 0.10a | — | — | NS |
Early hypertension | |||||||
Grade<2 | 17 | 1 | |||||
Grade⩾2 | 11 | 0.92 | 0.28–1.49 | 0.31 | |||
Early HFSR | |||||||
Grade<2 | 14 | 1 | |||||
Grade⩾2 | 14 | 0.65 | 0.32–1.75 | 0.49 | |||
Early rash | |||||||
Grade<2 | 7 | 1 | |||||
Grade⩾2 | 21 | 0.44 | 0.10–1.37 | 0.17a | — | — | NS |
Early diarrhoea | |||||||
Grade<2 | 19 | 1 | |||||
Grade⩾2 | 9 | 0.51 | 0.19–1.23 | 0.13a | — | — | NS |
Early toxicities | |||||||
Grade<2 | 8 | 1 | |||||
Grade⩾2 | 20 | 0.38 | 0.15–0.98 | 0.045 a | — | — | NS |
AUC max | |||||||
<100 | 12 | 1 | 1 | ||||
⩾100 | 15 | 0.28 | 0.11–0.72 | 0.009 a | 0.28 | 0.11–0.72 | 0.009 a |